Alectinib approved for the treatment of ALK-positive NSCLC

couple-1030744 1920
Are you looking for a
specific medicine?
A new treatment that targets a specific type of lung cancer has received FDA approval. Alectinib has been approved in the US for the treatment of patients with ALK (anaplastic lymphoma kinase)-positive non-small cell lung cancer (NSCLC) whose disease had worsened after – or who could not tolerate –  treatment with crizotinib [1].


Alectinib for ALK-positive NSCLC.

An ALK (anaplastic lymphoma kinase) is a gene mutation that can occur in various cancer cells, including lung cancer cells. ALK gene mutations are present in about 5 % of patients with NSCLC.

Alectinib is an oral medication that blocks the activity of the ALK protein, which may prevent NSCLC cells from growing and spreading [1]. Its approval provides a new therapy for patients who would have had few treatment options if their disease stopped responding to treatment with crizotinib. Furthermore, clinical trials provide evidence of an effect on tumours that had spread to the brain [1], which is common in ALK-positive NSCLC metastatic patients [2].

If you live outside the US you can order alectinib at when a doctor’s prescription is provided.

More information about the safety and efficacy of alectinib can be found at the following links:

DISCLAIMER: Nothing can replace the care of your clinician or doctor. Please do not make changes to your treatment or schedules without first consulting your healthcare providers. This article is not intended to diagnose or treat illness.

© TheSocialMedwork



Related Articles

First books, now medicines

Online shopping giants Amazon turn their eye to the online pharmacy market.

The pricing controversy surrounding Duchenne muscular dystrophy (DMD) treatment

The latest events surrounding the pricing of a Duchenne muscular dystrophy (DMD) treatment.

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.

Our service uses cookies.